Dr. Larry LaPointe leads Quest Diagnostics Research & Development for data and AI initiatives with a focus on genomics and oncology.

Prior to joining Quest, he was a co-founder and CEO of Clinical Genomics, a healthcare company that developed and marketed diagnostic tests for the early detection of cancer, including a “liquid biopsy” blood test for colorectal cancer based on detecting epigenetic changes in DNA methylation. Earlier, he was a co-founder of Enterix Inc, a cancer screening company, a consultant to biotech firms in the area of clinical diagnostics, and lab manager at the Center for Molecular Imaging Research at Massachusetts General Hospital.

Over the last two decades as a healthcare innovation leader, he has been awarded more than 20 global patents, has co-authored over 20 peer-reviewed publications and more than 50 conference presentations. Dr. LaPointe has a PhD in Bioinformatics from Flinders University (Australia) where he applied machine learning to identify new biomarkers for cancer, after receiving his BSc from Florida State University.

SXSW, Thought Leadership, Healthcare, Technology, Artificial Intelligence Data, Data Analytics, Leadership, Startup, Teamwork & Teambuilding, Cancer, Oncology, Genetics,